摘要
目的探讨参芪健胃颗粒联合替普瑞酮治疗慢性萎缩性胃炎的临床疗效。方法选取2015年4月—2016年4月在子洲县中医院接受治疗的慢性萎缩性胃炎患者82例,按照治疗方法的差别分成对照组(41例)和治疗组(41例)。对照组口服替普瑞酮胶囊,1粒/次,3次/d。治疗组在对照组的基础上口服参芪健胃颗粒,1袋/次,3次/d。两组患者均连续治疗4周。比较两组临床疗效、中医证候积分、白介素-6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)、超氧化酶歧化酶(SOD)、NO、丙二醛(MDA)、内皮素(ET)、表皮生长因子(EGF)和降钙素基因相关肽(CGRP)水平。结果治疗后,对照组和治疗组总有效率分别为80.49%和95.12%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者胃刺痛、倦怠乏力、胃脘胀满和食少纳呆症候评分均较同组治疗前显著降低(P<0.05);且治疗后治疗组这些症候评分显著低于对照组(P<0.05)。治疗后,两组IL-6、IL-8和TNF-α水平均低于同组治疗前(P<0.05);且治疗后治疗组这些观察指标显著低于对照组(P<0.05)。治疗后,两组患者血清SOD和NO水平明显升高,而MDA水平则降低,同组治疗前后差异具有统计学意义(P<0.05);且治疗组上述观察指标改善程度优于对照组(P<0.05)。治疗后,两组患者血清胃肠激素ET和EGF水平明显降低,而CGRP水平明显升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗组上述指标优于对照组(P<0.05)。结论参芪健胃颗粒联合替普瑞酮治疗慢性萎缩性胃炎效果显著,可明显改善患者临床症状、机体氧化应激状态和胃肠激素水平,降低血清炎性因子水平,具有一定的临床推广应用价值。
Objective To explore the clinical effect of Shenqi Jianwei Granules combined with teprenone in treatment of chronic atrophic gastritis. Methods Patients（82 cases） with chronic atrophic gastritis in Zizhou County Hospital of TCM from April 2015 to April 2016 were divided into the control（41 cases） and treatment（41 cases） groups based on different treatments. The patients in the control group were po administered with Teprenone Capsules, 1 grain/time, three times daily. The patients in the treatment group were po administered with Shenqi Jianwei Granules on the basis of the control group, 1 bag/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the TCM syndromes scores and the levels of IL-6, IL-8, TNF-α, SOD, NO, MDA, ET, EGF, and CGRP in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.49% and 95.12%, respectively, and there were differences between two groups（P〈0.05）. After treatment, the TCM syndromes scores of stomach pain, lassitude, gastric distention, and food less anorexia in two groups were significantly decreased（P〈0.05）. And these TCM syndromes scores in the treatment group were significantly lower than those in the control group（P〈0.05）. After treatment, IL-6, IL-8, and TNF-α levels in two groups were significantly decreased（P〈0.05）. And the observational indexes in the treatment group were significantly lower than those in the control group（P〈0.05）. After treatment, SOD and NO levels in two groups were significantly increased, and MDA was significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And the improvement of these observational indexes in the treatment group was significantly better than those in the control group（P〈0.05）. After treatment, ET and EGF levels in two groups were significantly decreased, and CGRP lev
出处
《现代药物与临床》
CAS
2016年第11期1750-1754,共5页
Drugs & Clinic
